Home/Filings/4/0000899243-21-036345
4//SEC Filing

NAGJI BANSI 4

Accession 0000899243-21-036345

CIK 0001809519other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 7:52 PM ET

Size

23.4 KB

Accession

0000899243-21-036345

Insider Transaction Report

Form 4
Period: 2021-09-14
Nagji Bansi
President, Healthcare
Transactions
  • Sale

    Class A Common Stock

    2021-09-15$45.03/sh60,415$2,720,4150 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-09-1629,788309,564 total
    Exercise: $6.84Exp: 2030-06-15Class A Common Stock (29,788 underlying)
  • Exercise/Conversion

    Class A Common Stock

    2021-09-15$6.84/sh+60,415$413,23960,415 total
  • Exercise/Conversion

    Class A Common Stock

    2021-09-16$6.84/sh+29,788$203,75029,788 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-09-1489,584481,250 total
    Exercise: $6.84Exp: 2030-06-15Class A Common Stock (89,797 underlying)
  • Exercise/Conversion

    Class A Common Stock

    2021-09-14$6.84/sh+89,797$614,21189,797 total
  • Sale

    Class A Common Stock

    2021-09-16$45.03/sh29,788$1,341,4880 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-09-14213399,787 total
    Exercise: $6.84Exp: 2030-06-15Class A Common Stock (213 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-09-1560,415339,372 total
    Exercise: $6.84Exp: 2030-06-15Class A Common Stock (60,415 underlying)
  • Sale

    Class A Common Stock

    2021-09-14$45.01/sh89,797$4,042,0230 total
Footnotes (6)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.11. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The option has vested and became exercisable or will vest and become exercisable with respect to the original 700,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on June 10, 2020.
  • [F6]The option vested and became exercisable as to 25,000 shares on the closing date of the Issuer's initial public offering of securities, and vested or will vest as to 1/48th of the shares monthly thereafter until fully vested on June 10, 2024.

Issuer

GoodRx Holdings, Inc.

CIK 0001809519

Entity typeother

Related Parties

1
  • filerCIK 0001632311

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 7:52 PM ET
Size
23.4 KB